

a2  
Cont

peptide comprises an amino acid sequence as shown in SEQ ID NO:174, wherein the isolated molecule inhibits ristocetin induced aggregation of platelets, and wherein the isolated molecule has a three dimensional structure complementary to the three dimensional structure of the isolated peptide.

#### REMARKS

In the Office Action, the Examiner required restriction to one of the following allegedly separate and distinct inventions:

- |           |   |
|-----------|---|
| Group I   | Claims 1-3, drawn to an isolated peptide;   |
| Group II  | Claims 4-6, drawn to a method of identifying a molecule that inhibits ristocetin induced aggregation of platelets;;                                   |
| Group III | Claims 7 and 9, drawn to a molecule identified by the method of Group II and to a molecule capable of binding to the isolated peptide of Group I; and |
| Group IV  | Claims 8 and 10, drawn to a method of modulating adhesion, aggregation, or agglutination of platelets using the molecule of Group III.                |

The Examiner also indicated that applicants are required to elect a particular species of peptide comprising SEQ ID NO:174, by identifying a preferred amino acid residue for Xaa at residue 3 and Xaa at residue 4.

In response to the restriction requirement, applicants hereby elect Group III, claims 7 and 9, for prosecution at this time. Claims 7 and 9 have each hereinabove been amended to be independent claims. Applicants further elect the species of peptide comprising SEQ ID NO:174 wherein amino acid residue 3 is tyrosine and wherein amino acid residue 4 is arginine.

Serial No.: 09/258,947

- 3 -

Please direct any questions concerning this response to applicants' undersigned attorney at the number provided.

Respectfully submitted,

October 6, 2000  
Date

Susan J. Braman  
Susan J. Braman  
Reg. No. 34,103

Braman & Rogalskyj, LLP  
P.O. Box 352  
Canandaigua, New York 14424-0352  
Tel: 716-393-3002  
Fax: 716-393-3001

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.	
10-06-00	<u>Susan J. Braman</u>
Date	Susan J. Braman Attorney Reg. No.: 34,103